FDA lifts partial clinical hold on Vigil Neuroscience's Phase I VG-3927 trial [Yahoo! Finance]
Vigil Neuroscience, Inc. (VIGL)
Company Research
Source: Yahoo! Finance
Vigil Neuroscience's Phase I trial of VG-3927, a novel treatment under development for neurodegenerative diseases. This decision follows a complete response submitted to the regulator by the company. In July this year, Vigil Neuroscience shared interim findings from the single- and multiple-ascending dose study of VG-3927 in healthy subjects. The safety and tolerability data from six SAD and two MAD cohorts indicated that VG-3927 is suitable for further clinical exploration. The pharmacokinetic (PK) profile also supported the potential of the asset for once-daily dosing. In addition, VG-3927 has shown promising signs of efficacy, including a sustained decline in soluble TREM2 levels in the cerebrospinal fluid (CSF), providing clinical evidence of target engagement. An increase in osteopontin/secreted phosphoprotein 1 (SPP1) was also observed after repeated doses of the treatment. The ongoing Phase I trial has now expanded to include patients suffering from Alzheimer's di
Show less
Read more
Impact Snapshot
Event Time:
VIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIGL alerts
High impacting Vigil Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
VIGL
News
- Vigil Neuroscience to Present at Upcoming Investor ConferencesGlobeNewswire
- Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target raised by analysts at Wedbush from $23.00 to $24.00. They now have an "outperform" rating on the stock.MarketBeat
- Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake [Yahoo! Finance]Yahoo! Finance
- Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Vigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceGlobeNewswire
VIGL
Earnings
- 11/7/24 - Beat
VIGL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- VIGL's page on the SEC website